THERAPY SUCCESS RATE WITH PEGYLATED INTERFERON/RIBAVIRIN TREATMENT OF RELAPSE AND NON-RESPONDER HEPATITIS C PATIENTS
Abstract
Faiqa Fateen1, Muhammad Noaman Yousaf2, Niamatullah Khan1,Faisal Nouman2, Waheed Iqbal1 and Sami Siraj1*
1Institute of Basic Medical Sciences, Khyber Medical University, Peshawar
2Mufti Mahmood Teaching Hospital, Dera Ismail Khan
Background: The combination therapy of Interferon and ribavirin remains the first line treatment in patients with chronic hepatitis C in Pakistan. Although the success rate of 24-week long treatment in treatment naïve patients’ genotype 3a hepatitis C patients is high, there are a few reports on retreatment of non-responder and relapse hepatitis C patients.This study was designed to assess the sustained virological response (SVR) rates in treatment-experienced patients, who had unfavorable outcome from their previous therapy.
Methodology: One hundred and thirty two (132) patients who had shown relapse (n=59) and non-response (n=73) to conventional IFN plus ribavirin were retreated with Pegylated IFN plus ribavirin. Outcomes at weak 12(early virological response [EVR]) and at week 24 (End of response [SVR]) were analyzed.
Results: One hundred and thirty two patients who had relapsed (n=59; 63%genotype3a) after previous conventional interferon plus ribavirin therapy or were nonresponders (n=73; 48% genotyp3a) were analyzed. Of the relapsers, 78% achieved an EVR and also the SVR. Of the non-responders, 81% achieved an EVR and also the SVR. SVR rates were 27% and 15% for genotype 3a and 2a respectively. EVR and low hepatitis C viral (HCV) RNA level on retreatment were associated with SVR. SVR rate for relapse and non-response patients was nearly equal.
Conclusion: Low baseline and at four weeks after start of therapy remain the most crucial predictors for treatment outcome in both relapse and non-responders. Viral genotype, on the other hand doesn’t seem to affect the therapy outcome significantly.
Key words: Chronic Hepatitis C; Pegylated Interferon plus ribavirin; Retreatment; Relapse; Nonresponders.
Address of corresponding author:
*Sami Siraj, PhD
Department of Pharmacology,
Institute of Basic Medical Sciences,
Khyber Medical University, Peshawar, Pakistan
References
Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9(1):34.
Re VL, Kostman J. Management of chronic hepatitis C. Postgraduate medical journal. 2005;81(956):376-82.
Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: consensus guidelines. Canadian Journal of gastroenterology. 2007;21(Suppl C):5C.
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of hepatology. 2006;44(1):97-103.
Yu M-L, Dai C-Y, Huang J-F, Hou N-J, Lee L-P, Hsieh M-Y, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56(4):553-9.
Ferreira SdC, Carneiro MdV, Souza FF, Teixeira AC, Villanova MG, Figueiredo JFdC, et al. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. Brazilian Journal of Infectious Diseases. 2010;14(4):330-4.
Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. Bmj. 2006;332(7548):1013-7.
Lindh M, Arnholm B, Eilard A, Farkkila M, Hellstrand K, Lagging M, et al. Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of viral hepatitis. 2011;18(6):400-7.
Cariani E, Villa E, Rota C, Critelli R, Trenti T. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2011;49(8):1247-56.
Qureshi MS, Iqbal M, Nomani AZ, Rasheed K. Time for change: conventional interferon regimes should not be the standard of care for management of Pakistani genotype-3 in chronic hepatitis C. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2014;24(1):70-2.
D'Souza R, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C, et al. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy. Alimentary pharmacology & therapeutics. 2005;21(1):43-7.
Umar M, Bilal M. Hepatitis C, A Mega Menace: A Pakistani Perspective. Journal of Pakistan Medical Students. 2012;2(2).
Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC, et al. A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C. The American journal of gastroenterology. 2005;100(11):2453-62.
Oze T, Hiramatsu N, Mita E, Akuta N, Sakamoto N, Nagano H, et al. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatology research : the official journal of the Japan Society of Hepatology. 2013;43(1):35-43.
Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Farkkila M, et al. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scandinavian journal of gastroenterology. 2013;48(7):839-47.
Ohno O, Mizokami M, Wu R-R, Saleh MG, Ohba K-i, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. Journal of clinical microbiology. 1997;35(1):201-7.
Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschenes M, Marotta PJ, et al. Retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Canadian Journal of Gastroenterology. 2009;23(3):180.
Morris Sherman M, Cooper CL, Mel Krajden M, MD10 RJB. Retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis С who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol. 2009;23(3).
Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MPJ, Paraná R, et al. R e-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin±amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial. Ann Hepatol. 2012;11:52-61.
Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004;40(6):1260-5.
Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, et al. Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3. PloS one. 2014;9(9):e107592.
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38(3):645-52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Faiqa Fateen, Muhammad Noaman Yousaf, Niamatullah Khan, Faisal Nouman, Waheed Iqbal, Sami Siraj
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
. 
